Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Sleep Initiation and Maintenance Disorders 1Skin Neoplasms 1Pain 1Melanoma 1Gastrointestinal Neoplasms 1Fatigue 1Colorectal Neoplasms 1Colonic Polyps 1Carcinoma, Neuroendocrine 1Anxiety Disorders 1

Interventions

Cisplatin 3Irinotecan 2tivozanib 1surufatinib 1sintilimab 1repotrectinib 1pralsetinib 1copper dotatate CU-64 1atezolizumab 1Topotecan 1Specimen Handling 1Nivolumab 1Neoadjuvant Therapy 1Melphalan 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interferon-alpha 1Gemcitabine 1Fluorodeoxyglucose F18 1Everolimus 1Etoposide 1Copper 1Carboplatin 1Biopsy 1BAY 1895344 1Aromatherapy 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Aromatherapy × Gastrointestinal × Clear all
NCT03858855 2020-08-04

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Ohio State University Comprehensive Cancer Center

Phase NA Completed
248 enrolled
DermatologicEndocrineGastrointestinal

Gastrointestinal Neoplasms, Melanoma, Skin Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡